US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Exelixis

37.43

+0.22000.59%

Post-market: 37.430.00000.00%18:18 EDT

Volume:1.71M

Turnover:63.75M

Market Cap:10.48B

PE:21.27

High:37.50

Open:37.06

Low:36.62

Close:37.21

Loading ...

Overview Company News Filings

Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?

Here's Why Exelixis (EXEL) is a Strong Value Stock

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Exelixis (EXEL) Gets a Buy from RBC Capital

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?

Exelixis Launches Special Equity Award Program

Guggenheim Remains a Buy on Exelixis (EXEL)

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL)

Exelixis Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Exelixis to present positive preclinical data across pipeline portfolio at AACR

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

BUZZ-U.S. STOCKS ON THE MOVE-SurgePays, B. Riley, CarMax

Exelixis Gains Buy Rating from Silvan Tuerkcan Following Early FDA Approval and Growth Potential in Neuroendocrine Tumor Market

Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET

Simply Wall St.

BUZZ-Exelixis' cancer drug gets FDA approval but analysts say its priced in; shares down

Exelixis Gets FDA Approval for Drug Treating Patients With Previously Treated Advanced Neuroendocrine Tumors

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EXEL/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EXEL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EXEL\",,,,,undefined,":{"symbol":"EXEL","market":"US","secType":"STK","nameCN":"Exelixis","latestPrice":37.43,"timestamp":1745611200000,"preClose":37.21,"halted":0,"volume":1709970,"hourTrading":{"tag":"盘后","latestPrice":37.43,"preClose":37.43,"latestTime":"18:18 EDT","volume":27335,"amount":1023160.85,"timestamp":1745619521164},"delay":0,"floatShares":235894721,"shares":279881450,"eps":1.76,"marketStatus":"Market Closed","change":0.22,"latestTime":"04-25 16:00:00 EDT","open":37.06,"high":37.5,"low":36.62,"amount":63754025.5887,"amplitude":0.02365,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.76,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":955425600000,"exchange":"NASDAQ","adjPreClose":37.21,"preHourTrading":{"tag":"盘前","latestPrice":37.1,"preClose":37.21,"latestTime":"09:28 EDT","volume":335,"amount":12460.139744999999,"timestamp":1745587699072},"postHourTrading":{"tag":"盘后","latestPrice":37.43,"preClose":37.43,"latestTime":"18:18 EDT","volume":27335,"amount":1023160.85,"timestamp":1745619521164},"volumeRatio":0.8287088389681556,"impliedVol":0.471,"impliedVolPercentile":0.524},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EXEL\",,,,,undefined,":{"symbol":"EXEL","floatShares":235894721,"roa":"14.64%","roe":"23.13%","lyrEps":1.797286,"volumeRatio":0.8287088389681556,"shares":279881450,"dividePrice":0,"high":37.5,"amplitude":0.02365,"preClose":37.21,"low":36.62,"week52Low":20.14,"pbRate":"4.67","psRate":"4.83","week52High":40.02,"institutionHeld":0.7772,"latestPrice":37.43,"eps":1.76,"divideRate":0,"volume":1709970,"delay":0,"ttmEps":1.76,"open":37.06,"prevYearClose":33.3,"prevWeekClose":36.19,"prevMonthClose":36.92,"prevQuarterClose":36.92,"fiveDayClose":36.19,"twentyDayClose":36.84,"sixtyDayClose":32.96},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EXEL\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530164386","title":"Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?","url":"https://stock-news.laohu8.com/highlight/detail?id=2530164386","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530164386?lang=en_us&edition=fundamental","pubTime":"2025-04-26 01:29","pubTimestamp":1745602140,"startTime":"0","endTime":"0","summary":"Investors will focus on lead drug Cabometyx’s performance when Exelixis EXEL reports first-quarter 2025 results shortly.The Zacks Consensus Estimate for sales and earnings is pegged at $502.8 million and 42 cents per share, respectively. . Exelixis beat on earnings in three of the trailing four quarters and missed in the remaining one, the average surprise being 26.87%. In the last reported quarter, the company beat on earnings by 7.84%.Exelixis generates revenues from net product sales, license revenues and collaboration and service revenues.Last month, the FDA approved the label expansion of Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors .Simultaneously, the drug was approved for adult and pediatric patients  with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET . Ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-q1-earnings-cabometyx-maintain-172900817.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EXEL"],"gpt_icon":0},{"id":"2529953060","title":"Here's Why Exelixis (EXEL) is a Strong Value Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2529953060","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529953060?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:40","pubTimestamp":1745502004,"startTime":"0","endTime":"0","summary":"It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.Why Investors Should Pay Attention to This Value Stock. Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks.EXEL sits at a Zacks Rank #3 , holds a Value Style Score of B, and has a VGM Score of A. Compared to the Medical - Biomedical and Genetics industry's P/E of 16X, shares of Exelixis are trading at a forward P/E of 16X. EXEL also has a PEG Ratio of 1, a Price/Cash Flow ratio of 19.1X, and a Price","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-exelixis-exel-strong-134004609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","BK4139","EXEL"],"gpt_icon":0},{"id":"2529535106","title":"Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2529535106","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529535106?lang=en_us&edition=fundamental","pubTime":"2025-04-22 22:01","pubTimestamp":1745330463,"startTime":"0","endTime":"0","summary":"Wall Street expects a year-over-year increase in earnings on higher revenues when Exelixis  reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower.While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.This drug developer is expected to post quarterly earnings of $0.41 per share in its upcoming report, which represents a year-over-year change of +141.2%.Revenues are expected to be $502.8 million, up 18.2% from the year-ago qu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-exel-earnings-expected-grow-140103261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EXEL","NVCR"],"gpt_icon":0},{"id":"2528022648","title":"Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term","url":"https://stock-news.laohu8.com/highlight/detail?id=2528022648","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528022648?lang=en_us&edition=fundamental","pubTime":"2025-04-16 21:50","pubTimestamp":1744811406,"startTime":"0","endTime":"0","summary":"Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.Is This 1 Momentum Stock a Screaming Buy Right Now?Momentum investors, who live by the saying \"the trend is your friend,\" are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.Alameda, CA-based Exelixis, Inc. is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-exelixis-exel-top-momentum-135006021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","EXEL","BK4139"],"gpt_icon":0},{"id":"2526845127","title":"Why Exelixis (EXEL) is a Top Value Stock for the Long-Term","url":"https://stock-news.laohu8.com/highlight/detail?id=2526845127","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526845127?lang=en_us&edition=fundamental","pubTime":"2025-04-08 21:40","pubTimestamp":1744119609,"startTime":"0","endTime":"0","summary":"For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.Why Investors Should Pay Attention to This Value Stock. Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks.Many value investors pay close attention to a company's earnings as well. For EXEL, six analysts revised their earnings estimate upwards in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-exelixis-exel-top-value-134009840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","EXEL","BK4532"],"gpt_icon":0},{"id":"2525768147","title":"Exelixis (EXEL) Gets a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2525768147","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525768147?lang=en_us&edition=fundamental","pubTime":"2025-04-05 09:48","pubTimestamp":1743817726,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Gregory Renza maintained a Buy rating on Exelixis (EXEL – Research Report) on April 3 and set a price target of $40.00. The com...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/exelixis-exel-gets-a-buy-from-rbc-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/exelixis-exel-gets-a-buy-from-rbc-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EXEL","BK4139","BK4532","BK4207"],"gpt_icon":0},{"id":"2524449342","title":"Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2524449342","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524449342?lang=en_us&edition=fundamental","pubTime":"2025-04-03 03:00","pubTimestamp":1743620400,"startTime":"0","endTime":"0","summary":"It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of Corcept Therapeutics Incorporated CORT skyrocketed after a late-stage study met its primary goal. On the other hand, Axsome Therapeutics’ AXSM shares declined after announcing results from a study on major depressive disorder .Shares of Corcept Therapeutics Incorporated surged on March 31 after the company announced the success of the late-stage ROSELLA study.The phase III ROSELLA study evaluated its pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer.Axsome Therapeutics announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder  with and without severe excessive daytime sleepiness .Nonetheless, in the prespecified subgroup of patients with severe EDS, treatment with solriamfetol led to greater improvements in depres","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-cort-study-190000499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1989771016.USD","LU0225284248.USD","LU1670711123.USD","BK4532","LU0096364046.USD","LU1670710588.SGD","LU1868836757.USD","LU2242646821.SGD","IE00BJT1NW94.SGD","IE00BSNM7G36.USD","LU1585245621.USD","LU2125154778.USD","LU2125154935.USD","IE00B2B36J28.USD","AXSM","LU0456855351.SGD","LU0882574055.USD","BK4588","LU1093756168.USD","BK4007","OS","LU0321505868.SGD","LU2242652126.USD","LU1074936037.SGD","LU0985481810.HKD","IE00BJJMRZ35.SGD","LU1718418525.SGD","BMY","BK4505","LU0306807586.USD","BK4534","LU1868836591.USD","LU1323610961.USD","PFS","BK4585","LU0306806265.USD","LU0321505439.SGD","CORT","EXEL","LU1291159041.SGD","LU1670711040.USD","LU1571399168.USD","LU2360032135.SGD","LU0566484027.USD","BK4097","BLUE","LU1093756325.SGD","BK4578","LU1670710661.SGD","BK4556"],"gpt_icon":1},{"id":"2524945144","title":"Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524945144","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524945144?lang=en_us&edition=fundamental","pubTime":"2025-04-02 21:48","pubTimestamp":1743601682,"startTime":"0","endTime":"0","summary":"We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where Exelixis, Inc.  stands against other most profitable biotech stocks to buy right now.With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction. The sector has bounced back from a difficult 2024 and is set to grow significantly, thanks to developments in AI-driven drug discovery, personalized medicine, and the rising demand for biologics. The global biotech market was expected to grow by a robust 13%, from $483.0 billion in 2024 to $546.0 billion in 2025, according to MarketsandMarkets. The sector’s resilience and growth potential are demonstrated by this expansion.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-inc-exel-most-profitable-134802137.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","USAW.SI","PSQ","TQQQ","EXEL","NQmain","QLD","QID","TSYW.SI","USJW.SI","MNQmain","BK4139","SQQQ",".IXIC","NVIW.SI"],"gpt_icon":1},{"id":"2524777829","title":"Exelixis Launches Special Equity Award Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2524777829","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524777829?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:37","pubTimestamp":1743453431,"startTime":"0","endTime":"0","summary":"An announcement from Exelixis ( ($EXEL) ) is now available. On March 28, 2025, Exelixis, Inc.’s Board of Directors approved a Special Equity Award ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/exelixis-launches-special-equity-award-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/exelixis-launches-special-equity-award-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","EQR","BK4532","EXEL","BK4215","BK4139","BK4585"],"gpt_icon":0},{"id":"2523066076","title":"Guggenheim Remains a Buy on Exelixis (EXEL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2523066076","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523066076?lang=en_us&edition=fundamental","pubTime":"2025-03-30 22:05","pubTimestamp":1743343514,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Michael Schmidt maintained a Buy rating on Exelixis (EXEL – Research Report) on March 26 and set a price target of $42.00. The c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-exelixis-exel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-exelixis-exel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4532","EXEL"],"gpt_icon":0},{"id":"2522537272","title":"FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537272","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537272?lang=en_us&edition=fundamental","pubTime":"2025-03-28 03:00","pubTimestamp":1743102000,"startTime":"0","endTime":"0","summary":"Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx .The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors .Simultaneously, the drug was approved for adult and pediatric patients  with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET .Consequently, Cabometyx is now the first and only systemic treatment that is FDA-approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin receptor expression and functional status.The approval came ahead of the target action date of April 3, 2025.The company is now focused on developing zanzalintinib, a next-generation oral TKI. In January 2025, results from an expansion cohort of the phase Ib/II STELLAR-001 study ev","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-expands-exelixis-cabometyx-label-190000158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","RCC","IE00BFTCPJ56.SGD","LU1323610961.USD","IE0009355771.USD","IE0002141913.USD","IE00B2B36J28.USD","LU0154236417.USD","BK4559","LU0306806265.USD","BMY","IE00BSNM7G36.USD","LU0321505868.SGD","BAYRY","LU1261432733.SGD","BK4588","LU0456854461.SGD","LU0096364046.USD","LU2360032135.SGD","LU1989771016.USD","IE00BKVL7J92.USD","LU0882574055.USD","BK4139","LU1670710661.SGD","LU0266512127.USD","LU1868836914.USD","IE00BFXG1179.USD","LU0321505439.SGD","LU1868836757.USD","LU1718418525.SGD","LU0456855351.SGD","EXEL","LU1074936037.SGD","LU2133065610.SGD","LU1670710588.SGD","LU2242646821.SGD","LU1032466523.USD","LU2125154935.USD","IE00BZ1G4Q59.USD","LU1585245621.USD","LU0225284248.USD","LU0985481810.HKD","LU1868837300.USD","LU1093756168.USD","DTC","CRC","LU1093756325.SGD","LU0237698245.USD"],"gpt_icon":1},{"id":"2522371147","title":"Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522371147","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522371147?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:38","pubTimestamp":1743075495,"startTime":"0","endTime":"0","summary":"In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Exelixis (EXEL – Research Report). The company’s ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-reaffirms-their-buy-rating-on-exelixis-exel-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-reaffirms-their-buy-rating-on-exelixis-exel-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EXEL"],"gpt_icon":0},{"id":"2522375336","title":"Exelixis Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375336","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375336?lang=en_us&edition=fundamental","pubTime":"2025-03-27 18:57","pubTimestamp":1743073020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EXEL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2025 06:57 ET (10:57 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL"],"gpt_icon":0},{"id":"2522966354","title":"Exelixis to present positive preclinical data across pipeline portfolio at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2522966354","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522966354?lang=en_us&edition=fundamental","pubTime":"2025-03-27 05:20","pubTimestamp":1743024023,"startTime":"0","endTime":"0","summary":"The company states: “Exelixis  announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research Annual Meeting 2025 taking place April 25-30 in Chicago, IL. Exelixis will present preclinical data for XL495 and XL309, small molecules that have demonstrated synthetic lethality in the context of certain genetic anomalies frequently found in some tumors. Preclinical data will also be presented for the PD-L1xNKG2A-targeting bispecific antibody XB628 and the tissue factor-targeting antibody-drug conjugate XB371. Initial details about the poster presentations can be found below. Full data will be presented at the AACR Annual Meeting.” “We are excited to share preclinical data from four of our pipeline molecules that constitute the next phase in our commitment to the discovery and development of innovative cancer treatments,” said Dana T. Aftab, Ph.D., Executive Vice President, Discovery & Translational Research, and Chief Scientific","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/exelixis-present-positive-preclinical-data-212023385.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-present-positive-preclinical-data-212023385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Exelixis to present positive preclinical data across pipeline portfolio at AACR","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","EXEL","BK4532"],"gpt_icon":0},{"id":"2522935496","title":"Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522935496","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522935496?lang=en_us&edition=fundamental","pubTime":"2025-03-27 03:00","pubTimestamp":1743015600,"startTime":"0","endTime":"0","summary":"Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe.The company's upbeat performance can be attributed to its strong quarterly results, raised guidance and efforts to increase shareholders' returns.Last month, Exelixis announced a new share repurchase program of $500 million. Shares rallied following the announcement. Earlier, the company reported better-than-expected fourth-quarter results, which also drove the stock higher.Let’s delve deeper and analyze the company’s strengths and weaknesses to understand how to play the stock in such a scenario.Exelixis’ lead drug Cabometyx maintains its status as the leading tyrosine kinase inhibitor  for the treatment of renal cell carcinoma  in both the frontline immuno-oncology  +TKI market and the second-line monotherapy segment.Meanwhile, Exelixis collaborated with pharma giant Merck MRK to evaluate zanzalinti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-stock-rises-13-3-190000591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1037948541.HKD","SG9999015341.SGD","BK4550","LU1934455277.USD","IE00BFTCPJ56.SGD","LU1989772840.SGD","IE00BFXG1179.USD","BK4559","LU1699723380.USD","LU1670710661.SGD","LU1037948897.HKD","LU1989772923.USD","BMY","BK4581","BK4585","LU2133065610.SGD","SG9999014567.USD","LU0306807586.USD","LU0289739699.SGD","LU1929549753.HKD","LU2023250504.SGD","MRK","LU0061475181.USD","LU1718418525.SGD","LU2242646821.SGD","CRC","LU1093756325.SGD","IE00BJT1NW94.SGD","BK4588","LU1670711123.USD","LU1868836914.USD","LU0266512127.USD","LU1670710588.SGD","LU1868837136.USD","SGXZ57979304.SGD","LU1868836591.USD","LU1941712264.USD","EXEL","RCC","SG9999015358.SGD","LU0306806265.USD","LU1868837300.USD","LU1323610961.USD","LU1934455194.USD","SG9999014542.SGD","LU1989771016.USD","LU1057294990.SGD","BK4516","LU1974910355.USD","LU1430594728.SGD"],"gpt_icon":0},{"id":"2522335502","title":"BUZZ-U.S. STOCKS ON THE MOVE-SurgePays, B. Riley, CarMax","url":"https://stock-news.laohu8.com/highlight/detail?id=2522335502","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522335502?lang=en_us&edition=fundamental","pubTime":"2025-03-27 01:40","pubTimestamp":1743010809,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-SurgePays,B. Riley, CarMaxEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nL6N3Q90QT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WING","LU2294711713.HKD","WVE","LU2506952170.USD","VRT","PVLA","VVX","IE00B894F039.SGD","IE00B29SXK94.USD","ALNY","CHWY","LU0256863811.USD","FCX","BBIO","LU0203345920.USD","EOG","BK4563","CVX","LU0266512127.USD","PSX","ULTA","HUMA","RILY","KMX","LU0823414551.USD","BK4127","COTY","LU0980610538.SGD","LU1023059063.AUD","XOM","BK4547","LU0050427557.USD","SURG","SG9999002232.USD","SCCO","DLTR","LU0054578231.USD","GWRS","SARO","COCO","CTAS","LU0075056555.USD","LU1582987597.SGD","JKS","AEP","LU0654597011.USD","EXEL"],"gpt_icon":1},{"id":"2522335625","title":"Exelixis Gains Buy Rating from Silvan Tuerkcan Following Early FDA Approval and Growth Potential in Neuroendocrine Tumor Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2522335625","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522335625?lang=en_us&edition=fundamental","pubTime":"2025-03-27 01:25","pubTimestamp":1743009920,"startTime":"0","endTime":"0","summary":"Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Silvan Tuerkcan from JMP Se...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/exelixis-gains-buy-rating-from-silvan-tuerkcan-following-early-fda-approval-and-growth-potential-in-neuroendocrine-tumor-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/exelixis-gains-buy-rating-from-silvan-tuerkcan-following-early-fda-approval-and-growth-potential-in-neuroendocrine-tumor-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EXEL"],"gpt_icon":0},{"id":"2522939335","title":"Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET","url":"https://stock-news.laohu8.com/highlight/detail?id=2522939335","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522939335?lang=en_us&edition=fundamental","pubTime":"2025-03-27 01:22","pubTimestamp":1743009724,"startTime":"0","endTime":"0","summary":"Exelixis saw an 11% share price increase over the last quarter, a period marked by significant achievements including the FDA's approval of CABOMETYX for treating a broader range of pancreatic and extra-pancreatic neuroendocrine tumors. This regulatory milestone adds to its existing portfolio, potentially enhancing market confidence. During the same period, the company reported robust earnings growth and initiated a $500 million share repurchase program, reflecting a strong financial position. Despite broader market volatility and declines in the tech sector, Exelixis's positive developments helped it outperform general market trends.View our complete analysis and fair value estimate and you decide.NasdaqGS:EXEL Earnings Per Share Growth as at Mar 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-nasdaqgs-exel-celebrates-fda-172204854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4588","NET","BK4607","BK4554","BK4532","BK4116","BK4560","BK4613","LU2286300806.USD","EXEL","BK4139","BK4585"],"gpt_icon":0},{"id":"2522387194","title":"BUZZ-Exelixis' cancer drug gets FDA approval but analysts say its priced in; shares down","url":"https://stock-news.laohu8.com/highlight/detail?id=2522387194","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522387194?lang=en_us&edition=fundamental","pubTime":"2025-03-27 00:30","pubTimestamp":1743006641,"startTime":"0","endTime":"0","summary":"BUZZ-Exelixis' cancer drug gets FDA approval but analysts say its priced in; shares down** Shares of cancer drugmaker Exelixis EXEL.O fall 2.3% to $36.83** US FDA approved EXEL's cancer drug, Cabometyx, for treating adult and pediatric patients with previously treated advanced neuroendocrine tumors ** Citizens Bank analyst Silvan Tuerkcan notes EXEL's shares declined as investors had already factored the approval into the stock price** Tuerkcan says investor focus will now be on the launch of the drug for patients with NET, and size of the opportunity, which is expected to drive \"a significant portion\" of the company's sales growth in the near term** Leerink Partners analyst Andrew Berens estimates Cabometyx to bring in $75 million for NET in 2025, with peak sales reaching $750 million before losing exclusivity impact starting in 2030** Stock gained ~59% in the last 12 months  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nL3N3Q91CB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL","BK4532","BK4139"],"gpt_icon":0},{"id":"2522802127","title":"Exelixis Gets FDA Approval for Drug Treating Patients With Previously Treated Advanced Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522802127","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522802127?lang=en_us&edition=fundamental","pubTime":"2025-03-26 21:59","pubTimestamp":1742997545,"startTime":"0","endTime":"0","summary":"Exelixis  said Wednesday it received approval for Cabometyx for patients with previously treated advanced neuroendocrine tumors from the US Food and Drug Administration.The approval was for the treatment of patients 12 years of age and older with previously treated, unresectable, pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.The company said the approval was based on a phase 3 trial that showed a statistically significant and clinically meaningful improvement in progression-free survival in patients with the treatment compared with those with a placebo.Price: 37.41, Change: -0.30, Percent Change: -0.81","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B66KJ199.SGD","AEIS","IE0031619046.USD","BK6522","BK4157","BK6088","IE00B7SZL793.SGD","BLZ.SI","BK4532","BK4139","IE00B19Z4B17.USD","EXEL"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EXEL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-11","symbol":"EXEL","fiscalQuarterEnding":"2024/12","expectedEps":0.45,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.48},{"market":"US","date":"2025-01-12","symbol":"EXEL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1736658000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-10-29","symbol":"EXEL","fiscalQuarterEnding":"2024/09","expectedEps":0.36,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730174400000,"reportTimeType":"post","actualEps":0.4},{"market":"US","date":"2024-08-06","symbol":"EXEL","fiscalQuarterEnding":"2024/06","expectedEps":0.31,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722916800000,"reportTimeType":"post","actualEps":0.75},{"market":"US","date":"2024-04-30","symbol":"EXEL","fiscalQuarterEnding":"2024/03","expectedEps":0.22,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1714449600000,"reportTimeType":"post","actualEps":0.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EXEL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EXEL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.35,"hold":0.45,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.35,"analysts":20,"updateTime":1740456000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EXEL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EXEL","date":"2025-04-24","current":19.748113,"percent":0.109285,"low":16.158427,"twenty":21.36213,"median":31.337682,"eighty":58.191612,"high":123.671097,"avg":38.329606,"sd":22.122831,"marketCap":10294039731},"quantilePoints":[{"date":"2020-05-01","current":22.952965,"twenty":-27.325861,"median":-2.655085,"eighty":16.258055,"marketCap":7368177253},{"date":"2020-05-08","current":27.133421,"twenty":-27.325861,"median":-2.655085,"eighty":16.384068,"marketCap":7973128644},{"date":"2020-05-15","current":26.882959,"twenty":-27.325861,"median":-2.655085,"eighty":16.477819,"marketCap":7899530533},{"date":"2020-05-22","current":25.693263,"twenty":-27.325861,"median":-2.655085,"eighty":16.669769,"marketCap":7549939508},{"date":"2020-05-29","current":25.787186,"twenty":-27.325861,"median":-2.655085,"eighty":16.772736,"marketCap":7577538799},{"date":"2020-06-05","current":23.345178,"twenty":-27.325861,"median":-2.655085,"eighty":16.914711,"marketCap":6859957221},{"date":"2020-06-12","current":23.36605,"twenty":-27.325861,"median":-2.655085,"eighty":17.072198,"marketCap":6866090397},{"date":"2020-06-19","current":25.234082,"twenty":-27.325861,"median":-2.655085,"eighty":17.193665,"marketCap":7415009638},{"date":"2020-06-26","current":23.877411,"twenty":-27.325861,"median":-2.498063,"eighty":17.327033,"marketCap":7016353206},{"date":"2020-07-02","current":24.503566,"twenty":-27.325861,"median":2.570279,"eighty":17.449214,"marketCap":7200348483},{"date":"2020-07-10","current":26.027212,"twenty":-27.325861,"median":7.700066,"eighty":17.686188,"marketCap":7648070322},{"date":"2020-07-17","current":25.672391,"twenty":-27.325861,"median":7.798866,"eighty":17.752451,"marketCap":7543806332},{"date":"2020-07-24","current":25.661955,"twenty":-27.325861,"median":7.918086,"eighty":17.906096,"marketCap":7540739744},{"date":"2020-07-31","current":24.096565,"twenty":-27.325861,"median":7.952297,"eighty":18.137028,"marketCap":7080751553},{"date":"2020-08-07","current":24.532882,"twenty":-27.325861,"median":8.048191,"eighty":18.372123,"marketCap":6909146512},{"date":"2020-08-14","current":24.115955,"twenty":-27.325861,"median":8.142361,"eighty":18.523046,"marketCap":6791728101},{"date":"2020-08-21","current":24.412193,"twenty":-27.325861,"median":8.236764,"eighty":18.814893,"marketCap":6875156972},{"date":"2020-08-28","current":23.731943,"twenty":-27.325861,"median":8.306231,"eighty":18.921262,"marketCap":6683579564},{"date":"2020-09-04","current":22.678653,"twenty":-27.325861,"median":8.452997,"eighty":19.15433,"marketCap":6386943578},{"date":"2020-09-11","current":23.84166,"twenty":-27.325861,"median":8.522074,"eighty":19.393808,"marketCap":6714479146},{"date":"2020-09-18","current":29.404349,"twenty":-27.325861,"median":8.639223,"eighty":21.878582,"marketCap":8281087949},{"date":"2020-09-25","current":26.156704,"twenty":-27.325861,"median":8.733376,"eighty":22.567702,"marketCap":7366460324},{"date":"2020-10-02","current":25.673946,"twenty":-27.325861,"median":8.760246,"eighty":22.741605,"marketCap":7230502164},{"date":"2020-10-09","current":26.233507,"twenty":-27.325861,"median":8.79746,"eighty":22.926619,"marketCap":7388090032},{"date":"2020-10-16","current":25.487426,"twenty":-27.325861,"median":8.876649,"eighty":23.321013,"marketCap":7177972875},{"date":"2020-10-23","current":24.45608,"twenty":-27.325861,"median":8.972487,"eighty":23.456447,"marketCap":6887516805},{"date":"2020-10-30","current":22.470189,"twenty":-27.325861,"median":8.98742,"eighty":23.487127,"marketCap":6328234373},{"date":"2020-11-06","current":42.232952,"twenty":-27.325861,"median":9.087264,"eighty":23.557982,"marketCap":6425152432},{"date":"2020-11-13","current":41.111363,"twenty":-27.325861,"median":9.098481,"eighty":23.685842,"marketCap":6254518253},{"date":"2020-11-20","current":38.562295,"twenty":-27.325861,"median":9.113834,"eighty":23.779449,"marketCap":5866713302},{"date":"2020-11-27","current":39.581922,"twenty":-27.325861,"median":9.129175,"eighty":23.84411,"marketCap":6021835283},{"date":"2020-12-04","current":38.705043,"twenty":-27.325861,"median":9.164612,"eighty":23.920269,"marketCap":5888430379},{"date":"2020-12-11","current":40.519979,"twenty":-27.325861,"median":9.190147,"eighty":24.042286,"marketCap":6164547505},{"date":"2020-12-18","current":40.683119,"twenty":-27.325861,"median":9.209534,"eighty":24.112523,"marketCap":6189367021},{"date":"2020-12-24","current":42.232952,"twenty":-27.325861,"median":9.239511,"eighty":24.160872,"marketCap":6425152432},{"date":"2020-12-31","current":40.92783,"twenty":-27.325861,"median":9.247119,"eighty":24.259288,"marketCap":6226596297},{"date":"2021-01-08","current":46.535778,"twenty":-27.325861,"median":9.290936,"eighty":24.393046,"marketCap":7079767190},{"date":"2021-01-15","current":48.381303,"twenty":-27.325861,"median":9.331472,"eighty":24.439962,"marketCap":7360537974},{"date":"2021-01-22","current":45.149086,"twenty":-27.325861,"median":9.352389,"eighty":24.47852,"marketCap":6868801296},{"date":"2021-01-29","current":45.291833,"twenty":-27.325861,"median":9.385679,"eighty":24.575729,"marketCap":6890518373},{"date":"2021-02-05","current":47.249517,"twenty":-27.325861,"median":9.422035,"eighty":24.692782,"marketCap":7188352576},{"date":"2021-02-12","current":61.152553,"twenty":-27.325861,"median":9.475859,"eighty":24.765611,"marketCap":6835693472},{"date":"2021-02-19","current":61.989876,"twenty":-27.325861,"median":9.52696,"eighty":24.818203,"marketCap":6929290370},{"date":"2021-02-26","current":60.454783,"twenty":-27.325861,"median":9.582451,"eighty":24.859848,"marketCap":6757696057},{"date":"2021-03-05","current":62.324806,"twenty":-27.329077,"median":9.628878,"eighty":24.949115,"marketCap":6966729130},{"date":"2021-03-12","current":64.976331,"twenty":-27.329077,"median":9.656734,"eighty":25.006772,"marketCap":7263119308},{"date":"2021-03-19","current":65.311261,"twenty":-27.329077,"median":9.710451,"eighty":25.161223,"marketCap":7300558067},{"date":"2021-03-26","current":63.329595,"twenty":-27.325861,"median":9.736947,"eighty":25.234082,"marketCap":7079045408},{"date":"2021-04-01","current":64.529759,"twenty":-27.325861,"median":9.747742,"eighty":25.270502,"marketCap":7213200962},{"date":"2021-04-09","current":64.529759,"twenty":-27.329077,"median":9.805299,"eighty":25.357929,"marketCap":7213200962},{"date":"2021-04-16","current":66.075436,"twenty":-27.329077,"median":9.834498,"eighty":25.412148,"marketCap":7385978281},{"date":"2021-04-23","current":69.268568,"twenty":-27.329077,"median":9.92067,"eighty":25.491815,"marketCap":7742909830},{"date":"2021-04-30","current":68.960459,"twenty":-27.329077,"median":9.944579,"eighty":25.677015,"marketCap":7708469067},{"date":"2021-05-07","current":121.493789,"twenty":-27.329077,"median":9.977077,"eighty":25.790166,"marketCap":7869152717},{"date":"2021-05-14","current":123.671097,"twenty":-27.329077,"median":10.042797,"eighty":25.900353,"marketCap":8010176959},{"date":"2021-05-21","current":118.348789,"twenty":-27.329077,"median":10.090291,"eighty":26.029567,"marketCap":7665451034},{"date":"2021-05-28","current":109.107325,"twenty":-27.329077,"median":10.142137,"eighty":26.116578,"marketCap":7066881472},{"date":"2021-06-04","current":108.236402,"twenty":-27.329077,"median":10.259913,"eighty":26.305665,"marketCap":7010471775},{"date":"2021-06-11","current":111.187864,"twenty":-27.329077,"median":10.30588,"eighty":26.528137,"marketCap":7201637970},{"date":"2021-06-18","current":108.429941,"twenty":-27.329077,"median":10.499122,"eighty":26.899667,"marketCap":7023007264},{"date":"2021-06-25","current":113.316788,"twenty":-27.329077,"median":10.577409,"eighty":27.427848,"marketCap":7339528341},{"date":"2021-07-02","current":88.350322,"twenty":-27.329077,"median":10.668743,"eighty":28.437015,"marketCap":5722450363},{"date":"2021-07-09","current":87.140707,"twenty":-27.329077,"median":10.768777,"eighty":32.735526,"marketCap":5644103562},{"date":"2021-07-16","current":81.286167,"twenty":-27.329077,"median":12.586346,"eighty":38.333898,"marketCap":5264905044},{"date":"2021-07-23","current":80.947475,"twenty":-27.329077,"median":13.259462,"eighty":38.843712,"marketCap":5242967939},{"date":"2021-07-30","current":81.52809,"twenty":-27.329077,"median":13.665176,"eighty":39.250255,"marketCap":5280574404},{"date":"2021-08-06","current":57.789598,"twenty":-27.329077,"median":14.041856,"eighty":39.491398,"marketCap":5434591593},{"date":"2021-08-13","current":61.240223,"twenty":-27.329077,"median":14.246084,"eighty":40.05544,"marketCap":5759091844},{"date":"2021-08-20","current":61.776243,"twenty":-27.329077,"median":14.431907,"eighty":40.44398,"marketCap":5809499650},{"date":"2021-08-27","current":65.092863,"twenty":-27.329077,"median":14.633356,"eighty":40.76874,"marketCap":6121397950},{"date":"2021-09-03","current":66.231905,"twenty":-27.329077,"median":14.930088,"eighty":41.024831,"marketCap":6228514538},{"date":"2021-09-10","current":66.868428,"twenty":-27.329077,"median":15.002715,"eighty":41.184268,"marketCap":6288373808},{"date":"2021-09-17","current":69.41452,"twenty":-27.329077,"median":15.270884,"eighty":41.645802,"marketCap":6527810887},{"date":"2021-09-24","current":68.174975,"twenty":-27.329077,"median":15.454005,"eighty":42.220717,"marketCap":6411242835},{"date":"2021-10-01","current":72.16162,"twenty":-27.329077,"median":15.627908,"eighty":42.663031,"marketCap":6786150893},{"date":"2021-10-08","current":72.42963,"twenty":-27.329077,"median":15.773963,"eighty":43.366777,"marketCap":6811354796},{"date":"2021-10-15","current":73.099654,"twenty":-27.329077,"median":15.952475,"eighty":44.822559,"marketCap":6874364554},{"date":"2021-10-22","current":71.692603,"twenty":-27.329077,"median":16.00116,"eighty":45.312226,"marketCap":6742044063},{"date":"2021-10-29","current":72.061116,"twenty":-27.329077,"median":16.265432,"eighty":45.826118,"marketCap":6776699429},{"date":"2021-11-05","current":37.285528,"twenty":-27.329077,"median":16.391679,"eighty":45.919924,"marketCap":6125452889},{"date":"2021-11-12","current":34.858887,"twenty":-27.329077,"median":16.479897,"eighty":45.919924,"marketCap":5726792216},{"date":"2021-11-19","current":34.724073,"twenty":-27.329077,"median":16.682751,"eighty":45.919924,"marketCap":5704644400},{"date":"2021-11-26","current":32.855945,"twenty":-27.200425,"median":16.81027,"eighty":45.919924,"marketCap":5397738961},{"date":"2021-12-03","current":30.506341,"twenty":-26.943119,"median":16.933764,"eighty":45.919924,"marketCap":5011734182},{"date":"2021-12-10","current":32.066324,"twenty":-26.245177,"median":17.104522,"eighty":45.919924,"marketCap":5268016044},{"date":"2021-12-17","current":35.051477,"twenty":-24.694911,"median":17.218287,"eighty":45.919924,"marketCap":5758431952},{"date":"2021-12-23","current":37.131455,"twenty":-24.254275,"median":17.32582,"eighty":45.919924,"marketCap":6100141100},{"date":"2021-12-31","current":35.20555,"twenty":7.517288,"median":17.464132,"eighty":45.919924,"marketCap":5783743740},{"date":"2022-01-07","current":36.091466,"twenty":7.709485,"median":17.687208,"eighty":45.891374,"marketCap":5929286526},{"date":"2022-01-14","current":34.897405,"twenty":7.799575,"median":17.756166,"eighty":45.891374,"marketCap":5733120163},{"date":"2022-01-21","current":33.356681,"twenty":7.907699,"median":17.862859,"eighty":45.891374,"marketCap":5480002275},{"date":"2022-01-28","current":34.223338,"twenty":7.943549,"median":18.081923,"eighty":45.891374,"marketCap":5622381087},{"date":"2022-02-04","current":36.187761,"twenty":8.039903,"median":18.360975,"eighty":45.891374,"marketCap":5945106394},{"date":"2022-02-11","current":36.110725,"twenty":8.136529,"median":18.515656,"eighty":45.891374,"marketCap":5932450500},{"date":"2022-02-18","current":27.042003,"twenty":8.217909,"median":18.789229,"eighty":45.891374,"marketCap":6248406283},{"date":"2022-02-25","current":27.899162,"twenty":8.270506,"median":18.897922,"eighty":45.891374,"marketCap":6446464151},{"date":"2022-03-04","current":28.61807,"twenty":8.371042,"median":19.106053,"eighty":45.891374,"marketCap":6612577201},{"date":"2022-03-11","current":29.019,"twenty":8.507031,"median":19.335948,"eighty":45.891374,"marketCap":6705217172},{"date":"2022-03-18","current":29.572006,"twenty":8.621808,"median":21.199768,"eighty":45.891374,"marketCap":6832996441},{"date":"2022-03-25","current":30.249439,"twenty":8.73225,"median":22.506564,"eighty":45.891374,"marketCap":6989526047},{"date":"2022-04-01","current":31.645779,"twenty":8.756029,"median":22.697854,"eighty":45.891374,"marketCap":7312168702},{"date":"2022-04-08","current":31.825506,"twenty":8.792498,"median":22.852188,"eighty":45.891374,"marketCap":7353696965},{"date":"2022-04-14","current":31.995647,"twenty":8.865935,"median":22.952956,"eighty":45.891374,"marketCap":7393010230},{"date":"2022-04-22","current":31.067233,"twenty":8.939729,"median":23.213643,"eighty":45.891374,"marketCap":7178488062},{"date":"2022-04-29","current":30.956378,"twenty":8.974263,"median":23.420305,"eighty":45.891374,"marketCap":7152873475},{"date":"2022-05-06","current":29.778539,"twenty":9.039592,"median":23.531551,"eighty":45.891374,"marketCap":6880718486},{"date":"2022-05-13","current":21.60979,"twenty":9.09473,"median":23.549925,"eighty":45.891374,"marketCap":6440473677},{"date":"2022-05-20","current":19.113041,"twenty":9.107191,"median":23.549925,"eighty":45.891374,"marketCap":5696355204},{"date":"2022-05-27","current":19.801799,"twenty":9.125872,"median":23.549925,"eighty":45.891374,"marketCap":5901629266},{"date":"2022-06-03","current":20.490558,"twenty":9.145972,"median":23.549925,"eighty":45.891374,"marketCap":6106903327},{"date":"2022-06-10","current":19.521991,"twenty":9.183299,"median":23.549925,"eighty":45.891374,"marketCap":5818236678},{"date":"2022-06-17","current":19.973989,"twenty":9.197529,"median":23.549925,"eighty":45.891374,"marketCap":5952947781},{"date":"2022-06-24","current":23.912825,"twenty":9.237499,"median":23.564333,"eighty":45.919924,"marketCap":7126858820},{"date":"2022-07-01","current":23.213305,"twenty":9.247736,"median":23.584442,"eighty":45.919924,"marketCap":6918377351},{"date":"2022-07-08","current":23.686826,"twenty":9.281845,"median":23.611294,"eighty":45.919924,"marketCap":7059503269},{"date":"2022-07-15","current":22.965782,"twenty":9.328108,"median":23.611294,"eighty":45.919924,"marketCap":6844606986},{"date":"2022-07-22","current":22.449214,"twenty":9.353834,"median":23.633017,"eighty":45.919924,"marketCap":6690651440},{"date":"2022-07-29","current":22.513785,"twenty":9.38718,"median":23.633017,"eighty":45.919924,"marketCap":6709895883},{"date":"2022-08-05","current":23.159496,"twenty":9.423477,"median":23.633017,"eighty":45.919924,"marketCap":6902340315},{"date":"2022-08-12","current":22.996839,"twenty":9.477679,"median":23.677084,"eighty":45.919924,"marketCap":6269283152},{"date":"2022-08-19","current":22.819758,"twenty":9.532448,"median":23.677084,"eighty":45.919924,"marketCap":6221008384},{"date":"2022-08-26","current":21.521169,"twenty":9.589879,"median":23.677084,"eighty":45.919924,"marketCap":5866993422},{"date":"2022-09-02","current":21.143397,"twenty":9.637235,"median":23.677084,"eighty":45.919924,"marketCap":5764007251},{"date":"2022-09-09","current":21.131592,"twenty":9.656291,"median":23.677084,"eighty":45.919924,"marketCap":5760788933},{"date":"2022-09-16","current":20.24619,"twenty":9.709392,"median":23.677084,"eighty":45.919924,"marketCap":5519415095},{"date":"2022-09-23","current":19.219124,"twenty":9.737158,"median":23.677084,"eighty":45.919924,"marketCap":5239421443},{"date":"2022-09-30","current":18.510802,"twenty":9.752596,"median":23.677084,"eighty":45.919924,"marketCap":5046322373},{"date":"2022-10-07","current":18.180252,"twenty":9.809283,"median":23.677084,"eighty":45.919924,"marketCap":4956209473},{"date":"2022-10-14","current":18.475386,"twenty":9.839263,"median":23.677084,"eighty":45.919924,"marketCap":5036667419},{"date":"2022-10-21","current":19.419815,"twenty":9.921087,"median":23.677084,"eighty":45.919924,"marketCap":5294132846},{"date":"2022-10-28","current":19.632311,"twenty":9.95111,"median":23.677084,"eighty":45.919924,"marketCap":5352062567},{"date":"2022-11-04","current":17.259423,"twenty":9.977849,"median":23.677084,"eighty":45.919924,"marketCap":5309360940},{"date":"2022-11-11","current":17.615936,"twenty":10.045835,"median":23.677084,"eighty":45.919924,"marketCap":5419031822},{"date":"2022-11-18","current":17.731278,"twenty":10.09551,"median":23.677084,"eighty":45.919924,"marketCap":5454513578},{"date":"2022-11-25","current":17.762735,"twenty":10.137764,"median":23.677084,"eighty":45.919924,"marketCap":5464190420},{"date":"2022-12-02","current":18.234591,"twenty":10.262522,"median":23.677084,"eighty":45.919924,"marketCap":5609343059},{"date":"2022-12-09","current":16.535911,"twenty":10.306552,"median":23.677084,"eighty":45.919924,"marketCap":5086793561},{"date":"2022-12-16","current":16.714168,"twenty":10.501618,"median":23.677084,"eighty":45.919924,"marketCap":5141629002},{"date":"2022-12-23","current":16.598825,"twenty":10.590509,"median":23.677084,"eighty":45.919924,"marketCap":5106147246},{"date":"2022-12-30","current":16.819025,"twenty":10.667114,"median":23.677084,"eighty":45.919924,"marketCap":5173885144},{"date":"2023-01-06","current":18.108763,"twenty":10.667114,"median":23.584442,"eighty":45.49168,"marketCap":5570635688},{"date":"2023-01-13","current":17.227966,"twenty":10.667114,"median":23.503875,"eighty":45.1654,"marketCap":5299684097},{"date":"2023-01-20","current":17.542536,"twenty":10.667114,"median":23.449537,"eighty":44.010071,"marketCap":5396452523},{"date":"2023-01-27","current":18.318476,"twenty":10.667114,"median":23.314972,"eighty":43.020435,"marketCap":5635147972},{"date":"2023-02-03","current":18.402362,"twenty":10.667114,"median":23.194326,"eighty":42.458135,"marketCap":5660952885},{"date":"2023-02-10","current":31.202932,"twenty":10.667114,"median":23.191781,"eighty":42.011762,"marketCap":5687732764},{"date":"2023-02-17","current":31.096255,"twenty":10.667114,"median":23.191781,"eighty":41.420955,"marketCap":5668287524},{"date":"2023-02-24","current":30.456195,"twenty":10.667114,"median":23.191781,"eighty":41.184268,"marketCap":5551616082},{"date":"2023-03-03","current":30.491754,"twenty":10.667114,"median":23.191781,"eighty":40.984929,"marketCap":5558097829},{"date":"2023-03-10","current":29.65612,"twenty":10.667114,"median":23.191781,"eighty":40.686627,"marketCap":5405776781},{"date":"2023-03-17","current":31.202932,"twenty":10.667114,"median":23.191781,"eighty":40.243946,"marketCap":5687732764},{"date":"2023-03-24","current":32.85642,"twenty":10.667114,"median":23.191781,"eighty":39.955417,"marketCap":5989133987},{"date":"2023-03-31","current":34.509909,"twenty":10.667928,"median":23.193053,"eighty":39.475483,"marketCap":6290535211},{"date":"2023-04-06","current":35.363322,"twenty":10.667928,"median":23.193053,"eighty":39.271956,"marketCap":6446097132},{"date":"2023-04-14","current":34.918836,"twenty":10.667114,"median":23.191781,"eighty":39.023166,"marketCap":6365075298},{"date":"2023-04-21","current":33.620936,"twenty":10.667114,"median":23.191781,"eighty":38.427704,"marketCap":6128491542},{"date":"2023-04-28","current":32.305257,"twenty":10.667114,"median":23.191781,"eighty":37.395181,"marketCap":5888666913},{"date":"2023-05-05","current":34.73643,"twenty":10.667114,"median":23.191781,"eighty":37.193084,"marketCap":6331825854},{"date":"2023-05-12","current":40.911234,"twenty":10.667114,"median":23.213305,"eighty":37.526354,"marketCap":6289570343},{"date":"2023-05-19","current":41.790934,"twenty":10.666299,"median":23.203815,"eighty":38.431783,"marketCap":6424812840},{"date":"2023-05-26","current":40.308235,"twenty":10.666299,"median":23.203815,"eighty":39.03948,"marketCap":6196867124},{"date":"2023-05-31","current":40.265872,"twenty":10.666299,"median":23.203815,"eighty":39.188346,"marketCap":6190354389},{"date":"2023-06-09","current":40.98604,"twenty":10.659474,"median":23.193053,"eighty":39.394311,"marketCap":6301070880},{"date":"2023-06-16","current":40.456505,"twenty":10.636307,"median":23.23296,"eighty":39.77769,"marketCap":6219661695},{"date":"2023-06-22","current":40.265872,"twenty":10.614439,"median":23.277876,"eighty":40.236218,"marketCap":6190354389},{"date":"2023-06-26","current":42.066293,"twenty":10.603505,"median":23.311527,"eighty":40.265872,"marketCap":6467145616},{"date":"2023-07-07","current":40.943677,"twenty":10.600095,"median":23.213305,"eighty":40.520035,"marketCap":6294558145},{"date":"2023-07-14","current":40.98604,"twenty":10.600095,"median":23.213305,"eighty":40.545455,"marketCap":6301070880},{"date":"2023-07-21","current":42.087474,"twenty":10.600095,"median":23.213305,"eighty":40.680159,"marketCap":6470401984},{"date":"2023-07-28","current":41.515576,"twenty":10.600095,"median":23.213305,"eighty":40.924511,"marketCap":6382480064},{"date":"2023-08-04","current":40.24272,"twenty":10.600095,"median":23.354574,"eighty":40.932036,"marketCap":6609585096},{"date":"2023-08-11","current":40.998725,"twenty":10.600095,"median":23.481924,"eighty":40.941559,"marketCap":6733753602},{"date":"2023-08-18","current":40.707954,"twenty":10.600095,"median":23.579987,"eighty":40.983764,"marketCap":6685996485},{"date":"2023-08-25","current":42.161809,"twenty":10.600095,"median":23.703849,"eighty":41.024602,"marketCap":6924782073},{"date":"2023-09-01","current":43.402433,"twenty":10.600095,"median":23.784876,"eighty":41.205168,"marketCap":7128545776},{"date":"2023-09-08","current":42.685197,"twenty":10.600095,"median":23.881479,"eighty":41.417849,"marketCap":7010744885},{"date":"2023-09-15","current":43.169816,"twenty":10.600095,"median":23.959006,"eighty":41.704282,"marketCap":7090340081},{"date":"2023-09-22","current":41.832269,"twenty":10.600095,"median":24.063445,"eighty":41.742049,"marketCap":6870657340},{"date":"2023-09-29","current":43.402433,"twenty":10.600095,"median":24.159779,"eighty":41.859163,"marketCap":7128545776},{"date":"2023-10-06","current":42.917814,"twenty":10.600095,"median":24.411169,"eighty":41.925256,"marketCap":7048950579},{"date":"2023-10-13","current":41.173188,"twenty":10.600095,"median":24.472259,"eighty":41.970666,"marketCap":6762407873},{"date":"2023-10-20","current":40.378413,"twenty":10.600095,"median":24.601456,"eighty":42.032402,"marketCap":6631871751},{"date":"2023-10-27","current":40.688569,"twenty":10.590509,"median":24.763289,"eighty":42.053584,"marketCap":6682812677},{"date":"2023-11-03","current":67.987802,"twenty":10.590509,"median":24.82708,"eighty":42.104419,"marketCap":6259908894},{"date":"2023-11-10","current":70.993721,"twenty":10.590509,"median":24.916894,"eighty":42.169563,"marketCap":6536675855},{"date":"2023-11-17","current":70.858623,"twenty":10.590509,"median":25.114925,"eighty":42.251018,"marketCap":6524236890},{"date":"2023-11-24","current":73.222829,"twenty":10.590509,"median":25.234082,"eighty":42.431195,"marketCap":6741918769},{"date":"2023-12-01","current":73.661896,"twenty":10.590509,"median":25.380185,"eighty":42.822269,"marketCap":6782345404},{"date":"2023-12-08","current":74.269835,"twenty":10.594875,"median":25.475549,"eighty":42.99923,"marketCap":6838320744},{"date":"2023-12-15","current":78.728051,"twenty":10.594875,"median":25.683605,"eighty":43.169816,"marketCap":7248806574},{"date":"2023-12-22","current":79.302215,"twenty":10.594875,"median":25.809174,"eighty":43.432834,"marketCap":7301672173},{"date":"2023-12-29","current":81.497549,"twenty":10.590509,"median":25.871438,"eighty":43.801759,"marketCap":7503805346},{"date":"2024-01-05","current":79.741282,"twenty":10.586142,"median":26.026128,"eighty":45.173557,"marketCap":7342098807},{"date":"2024-01-12","current":75.688358,"twenty":10.586142,"median":26.123266,"eighty":45.499837,"marketCap":6968929872},{"date":"2024-01-19","current":75.215517,"twenty":10.581776,"median":26.310309,"eighty":46.429737,"marketCap":6925393496},{"date":"2024-01-26","current":74.607578,"twenty":10.586142,"median":26.757641,"eighty":47.070063,"marketCap":6869418156},{"date":"2024-02-02","current":73.45925,"twenty":10.586142,"median":26.8819,"eighty":48.970648,"marketCap":6763686957},{"date":"2024-02-09","current":29.434352,"twenty":10.586142,"median":27.133306,"eighty":50.736642,"marketCap":6115428204},{"date":"2024-02-16","current":30.047264,"twenty":10.666299,"median":27.737543,"eighty":50.736642,"marketCap":6242769792},{"date":"2024-02-23","current":30.222382,"twenty":10.755729,"median":28.081886,"eighty":50.736642,"marketCap":6279153103},{"date":"2024-03-01","current":31.958965,"twenty":12.580654,"median":28.465994,"eighty":50.389968,"marketCap":6639954272},{"date":"2024-03-08","current":32.236234,"twenty":14.477572,"median":28.687196,"eighty":50.389968,"marketCap":6697561181},{"date":"2024-03-15","current":32.995077,"twenty":15.693391,"median":29.087177,"eighty":50.389968,"marketCap":6855222195},{"date":"2024-03-22","current":34.906778,"twenty":16.21505,"median":29.378454,"eighty":50.389968,"marketCap":7252406675},{"date":"2024-03-28","current":34.819219,"twenty":16.431775,"median":29.448945,"eighty":50.389968,"marketCap":7234215019},{"date":"2024-04-05","current":34.279273,"twenty":16.579951,"median":29.605173,"eighty":50.736642,"marketCap":7122033143},{"date":"2024-04-12","current":33.05345,"twenty":16.813772,"median":29.772048,"eighty":50.736642,"marketCap":6867349966},{"date":"2024-04-19","current":31.911299,"twenty":16.916749,"median":30.058488,"eighty":50.736642,"marketCap":6630050987},{"date":"2024-04-26","current":33.386966,"twenty":17.091652,"median":30.249439,"eighty":50.389968,"marketCap":6936642941},{"date":"2024-05-03","current":31.422916,"twenty":17.176551,"median":30.506341,"eighty":50.389968,"marketCap":6443394612},{"date":"2024-05-10","current":30.911512,"twenty":17.328629,"median":30.882901,"eighty":50.389968,"marketCap":6338529239},{"date":"2024-05-17","current":30.158612,"twenty":17.488992,"median":30.882901,"eighty":50.389968,"marketCap":6184144105},{"date":"2024-05-24","current":28.993748,"twenty":17.580284,"median":30.882901,"eighty":50.389968,"marketCap":5945284088},{"date":"2024-05-31","current":29.519358,"twenty":17.615936,"median":30.882901,"eighty":50.389968,"marketCap":6053062389},{"date":"2024-06-07","current":31.50815,"twenty":17.668364,"median":30.926871,"eighty":50.389968,"marketCap":6460872174},{"date":"2024-06-14","current":31.195625,"twenty":17.731278,"median":31.024392,"eighty":50.736642,"marketCap":6396787779},{"date":"2024-06-21","current":30.868895,"twenty":17.766317,"median":31.025137,"eighty":51.083315,"marketCap":6329790457},{"date":"2024-06-28","current":32.005348,"twenty":17.852912,"median":31.063965,"eighty":53.63882,"marketCap":6562824621},{"date":"2024-07-05","current":31.195625,"twenty":17.982935,"median":31.110391,"eighty":53.63882,"marketCap":6396787779},{"date":"2024-07-12","current":32.033759,"twenty":18.146511,"median":31.178387,"eighty":53.63882,"marketCap":6568650475},{"date":"2024-07-15","current":31.820674,"twenty":18.176822,"median":31.195625,"eighty":53.63882,"marketCap":6524956569},{"date":"2024-08-02","current":34.406104,"twenty":18.456098,"median":31.288944,"eighty":57.789598,"marketCap":7055109290},{"date":"2024-08-09","current":22.14419,"twenty":18.510802,"median":31.323476,"eighty":57.789598,"marketCap":7750289368},{"date":"2024-08-16","current":21.44327,"twenty":18.768662,"median":31.323476,"eighty":57.789598,"marketCap":7504972884},{"date":"2024-08-23","current":21.011307,"twenty":18.973137,"median":31.323476,"eighty":57.789598,"marketCap":7353789470},{"date":"2024-08-30","current":21.206913,"twenty":19.112302,"median":31.323476,"eighty":57.789598,"marketCap":7422249884},{"date":"2024-09-06","current":20.840152,"twenty":19.183708,"median":31.323476,"eighty":57.789598,"marketCap":7293886608},{"date":"2024-09-13","current":21.44327,"twenty":19.289956,"median":31.323476,"eighty":57.789598,"marketCap":7504972884},{"date":"2024-09-20","current":21.867082,"twenty":19.478842,"median":31.323476,"eighty":57.789598,"marketCap":7653303781},{"date":"2024-09-27","current":21.386218,"twenty":19.575801,"median":31.323476,"eighty":57.789598,"marketCap":7485005264},{"date":"2024-10-04","current":21.386218,"twenty":19.877132,"median":31.323476,"eighty":57.789598,"marketCap":7485005264},{"date":"2024-10-11","current":20.954256,"twenty":20.21075,"median":31.323476,"eighty":57.789598,"marketCap":7333821849},{"date":"2024-10-18","current":23.684585,"twenty":20.318368,"median":31.323476,"eighty":57.789598,"marketCap":8289415128},{"date":"2024-10-25","current":22.910312,"twenty":20.693448,"median":31.323476,"eighty":57.789598,"marketCap":8018425989},{"date":"2024-10-31","current":19.840881,"twenty":20.791251,"median":31.323476,"eighty":57.789598,"marketCap":9264183408},{"date":"2024-11-08","current":21.895917,"twenty":20.951195,"median":31.330579,"eighty":57.923603,"marketCap":10223728916},{"date":"2024-11-15","current":21.437203,"twenty":20.974348,"median":31.330579,"eighty":57.923603,"marketCap":10009544651},{"date":"2024-11-22","current":21.302647,"twenty":21.045396,"median":31.330579,"eighty":57.923603,"marketCap":9946717266},{"date":"2024-11-29","current":22.299584,"twenty":21.095503,"median":31.330579,"eighty":57.923603,"marketCap":10412211069},{"date":"2024-12-06","current":22.042705,"twenty":21.156382,"median":31.330579,"eighty":57.923603,"marketCap":10292267880},{"date":"2024-12-13","current":21.516713,"twenty":21.234624,"median":31.330579,"eighty":57.923603,"marketCap":10046669923},{"date":"2024-12-20","current":20.599287,"twenty":21.262689,"median":31.330579,"eighty":57.923603,"marketCap":9618301393},{"date":"2024-12-27","current":20.813353,"twenty":21.262689,"median":31.330579,"eighty":57.923603,"marketCap":9718254050},{"date":"2025-01-03","current":20.758307,"twenty":21.262689,"median":31.330579,"eighty":57.923603,"marketCap":9692551938},{"date":"2025-01-10","current":21.100813,"twenty":21.272083,"median":31.337682,"eighty":58.057608,"marketCap":9852476190},{"date":"2025-01-17","current":22.35463,"twenty":21.382958,"median":31.337682,"eighty":58.057608,"marketCap":10437913181},{"date":"2025-01-24","current":20.874515,"twenty":21.386218,"median":31.337682,"eighty":58.057608,"marketCap":9746811952},{"date":"2025-01-31","current":20.140573,"twenty":21.386218,"median":31.337682,"eighty":58.057608,"marketCap":9404117128},{"date":"2025-02-07","current":20.593171,"twenty":21.386218,"median":31.337682,"eighty":58.057608,"marketCap":9615445603},{"date":"2025-02-14","current":18.518554,"twenty":21.386218,"median":31.337682,"eighty":58.057608,"marketCap":9653111210},{"date":"2025-02-21","current":18.840709,"twenty":21.386218,"median":31.337682,"eighty":58.057608,"marketCap":9821040080},{"date":"2025-02-28","current":20.215238,"twenty":21.386218,"median":31.337682,"eighty":58.057608,"marketCap":10537536592},{"date":"2025-03-07","current":20.515916,"twenty":21.399258,"median":31.337682,"eighty":58.191612,"marketCap":10694270204},{"date":"2025-03-14","current":19.758852,"twenty":21.399258,"median":31.337682,"eighty":58.191612,"marketCap":10299637360},{"date":"2025-03-21","current":19.962883,"twenty":21.399258,"median":31.337682,"eighty":58.191612,"marketCap":10405992311},{"date":"2025-03-28","current":19.780329,"twenty":21.399258,"median":31.337682,"eighty":58.191612,"marketCap":10310832618},{"date":"2025-04-04","current":19.694421,"twenty":21.399258,"median":31.337682,"eighty":58.191612,"marketCap":10266051586},{"date":"2025-04-11","current":18.502446,"twenty":21.386218,"median":31.337682,"eighty":58.057608,"marketCap":9644714767},{"date":"2025-04-17","current":19.40985,"twenty":21.386218,"median":31.337682,"eighty":58.057608,"marketCap":10117714417},{"date":"2025-04-24","current":19.748113,"twenty":21.36213,"median":31.337682,"eighty":58.191612,"marketCap":10294039731}],"updateTime":1745646971572}}}